Akero Therapeutics Announces New Phase 2b Clinical Data for Efruxifermin in MASH at Upcoming AASLD 2025 Liver Meeting

Reuters

10/07

<a href="https://laohu8.com/S/AKRO">Akero Therapeutics</a> Announces New Phase 2b Clinical Data for Efruxifermin in MASH at Upcoming AASLD 2025 Liver Meeting

Akero Therapeutics Inc. has announced upcoming presentations of new data from its Phase 2b SYMMETRY and HARMONY studies evaluating efruxifermin $(EFX)$, the company's lead product candidate, at the 76th Annual American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025, scheduled for November 7-11, 2025, in Washington, DC. The presentations will include findings from the 96-week SYMMETRY study assessing the safety and efficacy of efruxifermin in patients with compensated cirrhosis (F4c) due to metabolic dysfunction-associated steatohepatitis (MASH), as well as results from an AI-powered digital analysis of histology data from the 96-week HARMONY study in patients with pre-cirrhotic (F2-F3) MASH. The results from these studies will be presented at the conference and have not yet been publicly disclosed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akero Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9541115-en) on October 07, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2573951420"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2573951420\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2573951420?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-07 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2573951420","market":"fut","top_or_hot":-1,"title":"Akero Therapeutics Announces New Phase 2b Clinical Data for Efruxifermin in MASH at Upcoming AASLD 2025 Liver Meeting","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/AKRO\">Akero Therapeutics</a> Announces New Phase 2b Clinical Data for Efruxifermin in MASH at Upcoming AASLD 2025 Liver Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Akero <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. has announced upcoming presentations of new data from its Phase 2b SYMMETRY and HARMONY studies evaluating efruxifermin <a href=\"https://laohu8.com/S/EFX\">$(EFX)$</a>, the company's lead product candidate, at the 76th Annual American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025, scheduled for November 7-11, 2025, in Washington, DC. The presentations will include findings from the 96-week SYMMETRY study assessing the safety and efficacy of efruxifermin in patients with compensated cirrhosis (F4c) due to metabolic dysfunction-associated steatohepatitis (MASH), as well as results from an AI-powered digital analysis of histology data from the 96-week HARMONY study in patients with pre-cirrhotic (F2-F3) MASH. The results from these studies will be presented at the conference and have not yet been publicly disclosed.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akero Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9541115-en) on October 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Akero Therapeutics Announces New Phase 2b Clinical Data for Efruxifermin in MASH at Upcoming AASLD 2025 Liver Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAkero Therapeutics Announces New Phase 2b Clinical Data for Efruxifermin in MASH at Upcoming AASLD 2025 Liver Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-07 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/AKRO\">Akero Therapeutics</a> Announces New Phase 2b Clinical Data for Efruxifermin in MASH at Upcoming AASLD 2025 Liver Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Akero <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. has announced upcoming presentations of new data from its Phase 2b SYMMETRY and HARMONY studies evaluating efruxifermin <a href=\"https://laohu8.com/S/EFX\">$(EFX)$</a>, the company's lead product candidate, at the 76th Annual American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025, scheduled for November 7-11, 2025, in Washington, DC. The presentations will include findings from the 96-week SYMMETRY study assessing the safety and efficacy of efruxifermin in patients with compensated cirrhosis (F4c) due to metabolic dysfunction-associated steatohepatitis (MASH), as well as results from an AI-powered digital analysis of histology data from the 96-week HARMONY study in patients with pre-cirrhotic (F2-F3) MASH. The results from these studies will be presented at the conference and have not yet been publicly disclosed.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akero Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9541115-en) on October 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251007:nNDL1hyJF2:1","article_id":"2573951420","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2573951420","pubTimestamp":1759834838,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Akero Therapeutics Inc. has announced upcoming presentations of new data from its Phase 2b SYMMETRY and HARMONY studies evaluating efruxifermin , the company's lead product candidate, at the 76th Annual American Association for the Study of Liver Diseases  The Liver Meeting 2025, scheduled for November 7-11, 2025, in Washington, DC. The presentations will include findings from the 96-week SYMMETRY study assessing the safety and efficacy of efruxifermin in patients with compensated cirrhosis  due to metabolic dysfunction-associated steatohepatitis , as well as results from an AI-powered digital analysis of histology data from the 96-week HARMONY study in patients with pre-cirrhotic  MASH. The results from these studies will be presented at the conference and have not yet been publicly disclosed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4112":"金融交易所和数据","BK4585":"ETF&股票定投概念","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4505":"高瓴资本持仓","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4139":"生物科技","NDAQ":"纳斯达克OMX交易所","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","AKRO":"Akero Therapeutics","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC"},"translate_title":"Akero Therapeutics在即将举行的AASLD 2025肝脏会议上宣布了Efruxifermin在MASH中的新2b期临床数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AKRO":0.9,"NDAQ":0.9},"content_text":"Akero Therapeutics Announces New Phase 2b Clinical Data for Efruxifermin in MASH at Upcoming AASLD 2025 Liver Meeting\n    \n\n        Akero Therapeutics Inc. has announced upcoming presentations of new data from its Phase 2b SYMMETRY and HARMONY studies evaluating efruxifermin $(EFX)$, the company's lead product candidate, at the 76th Annual American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025, scheduled for November 7-11, 2025, in Washington, DC. The presentations will include findings from the 96-week SYMMETRY study assessing the safety and efficacy of efruxifermin in patients with compensated cirrhosis (F4c) due to metabolic dysfunction-associated steatohepatitis (MASH), as well as results from an AI-powered digital analysis of histology data from the 96-week HARMONY study in patients with pre-cirrhotic (F2-F3) MASH. The results from these studies will be presented at the conference and have not yet been publicly disclosed.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akero Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9541115-en) on October 07, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}